Evaluation of CPD MNV as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)

Evaluation of CPD (Cell Population Data) MNV (Mean Neutrophil Volume) as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02232750

Acronym

Beckman

Enrollment

1320

Registered

2014-09-05

Start date

2014-07-14

Completion date

2015-08-15

Last updated

2021-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Severe Sepsis and Septic Shock

Brief summary

The investigators hypothesize that CPD parameters will provide improved prediction of sepsis compared to currently employed laboratory parameters. These studies hold the potential to shape practitioner guidelines and improve the timeliness and accuracy with which patients with sepsis are treated today.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Adult (≥18 to 90 years) * Patients presenting to the Emergency Department * CBC (Complete Blood Count) with differential testing performed and CPD data retrieved

Exclusion criteria

* Previously enrolled in this study

Design outcomes

Primary

Measure	Time frame	Description
We are measuring CBC (complete blood count) and MNV (Mean Neutrophil Volume)	approximately 10 months	Evaluate the clinical utility of CPD MNV as an aid in the diagnosis and risk assessment of Emergency Department patients for progression to sepsis, severe sepsis and septic shock.

Countries

United States

Outcome results